Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

ARS Pharmaceuticals Securities Class Action

ARS Pharmaceuticals · ARS Pharmaceuticals securities · Ongoing Litigation

About this case

A securities class action has been filed against ARS Pharmaceuticals on behalf of investors who purchased or acquired ARS securities between March 9, 2026 and June 24, 2026. The complaint alleges that disclosures about payer access and formulary coverage for the company's neffy product misled investors, followed by a decline in ARS's stock price; the matter is ongoing, with a lead-plaintiff deadline of October 5, 2026.

Case overview

Defendant company
ARS Pharmaceuticals
Product or service
ARS Pharmaceuticals securities
Case name
ARS Pharmaceuticals, Inc. Securities Fraud Class Action
Court case number
3:26-cv-04469
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

settlement claim
Lead Plaintiff Application

Participation information

Settlement Claim

Investors who purchased or otherwise acquired ARS Pharmaceuticals, Inc. securities from 2026-03-09 through 2026-06-24, inclusive, and suffered a loss may participate in the putative class action. Investors wishing to seek appointment as lead plaintiff must apply by 2026-10-05.

A qualified investor may move the United States District Court for the Southern District of California for appointment as lead plaintiff by 2026-10-05, through counsel of the investor’s choice. No official court filing form or settlement claim form was verified.

Type
Settlement Claim
Status
Open
Payout
No settlement has been verified. This is a newly filed securities class action in which investors may seek appointment as lead plaintiff; seeking lead-plaintiff status is not required to potentially share in any later recovery.

Lead Plaintiff Application

Investors who purchased or otherwise acquired ARS securities during the period from March 9, 2026 through June 24, 2026 may seek appointment as lead plaintiff.

Move the court no later than October 5, 2026 to serve as lead plaintiff. Investors do not need to seek lead-plaintiff status to potentially share in any recovery.

Type
Lead Plaintiff
Status
Open
Reported proof requirement
Unclear
Apply as lead plaintiff

Pomerantz LLP Investor Inquiry

Investors with losses on their investment in ARS Pharmaceuticals are invited to contact Pomerantz LLP regarding the filed class action.

Contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, or toll-free at 888-4-POMLAW, extension 7980. Email inquiries are encouraged to include a mailing address, telephone number, and number of shares purchased.

Type
Law Firm Signup
Reported proof requirement
Unclear

Settlement Claim

Investors who purchased or otherwise acquired ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026, inclusive, may be members of the proposed securities class. The action alleges that ARS and certain officers or directors made materially false or misleading statements or omitted material information concerning expected expanded insurance coverage for neffy.

No settlement claim-filing process has been verified. Investors within the class period may seek appointment as lead plaintiff by filing a motion with the United States District Court for the Southern District of California by October 5, 2026.

Type
Settlement Claim
Reported proof requirement
Unclear

Sources